Welcome to Verona Pharma's second quarter 2021 financial results and operating highlights conference call. At this time, all participants are in a listen-only mode. Earlier this morning, Verona Pharma issued a press release announcing its financial results for the three and six months ended June 30th, 2021. A copy can be found in the investor relations tab on the corporate website, www.veronapharma.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from our expectations expressed or implied by forward-looking statements, including, without limitation, the impact of COVID-19 pandemic on the status, recruitment, timing, results, and costs of our clinical trials and the continuity of our business. Any such forward-looking statements represent management's estimates as of the date of this conference call. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. As a reminder, this call is being recorded and will remain available for 90 days. I'd now like to turn the call over to Dr. David Zaccardelli, Chief Executive Officer. Please go ahead. Thank you. Welcome everyone to today's call. With me are Mark Hahn, our Chief Financial Officer, Dr. Kathleen Rickard, our Chief Medical Officer, and Chris Martin, our Vice President of Commercial. During the second quarter of 2021, we continued steady progress towards our goal of delivering ensifentrine, a novel inhaled PDE3 and PDE4 inhibitor and first-in-class product candidate for the maintenance treatment of COPD via our phase III ENHANCE program. As a reminder, each of the two randomized double-blind placebo-controlled ENHANCE studies are planned to enroll approximately 800 moderate to severe symptomatic COPD patients for a total of 1,600 patients across sites in the U.S., Europe, and Asia. The ENHANCE-1 and ENHANCE-2 trials will replicate measurements of efficacy and safety data over 24 weeks with ENHANCE-1 also evaluating longer-term safety in approximately 400 patients over 48 weeks. As discussed in previous calls, our projections of completing enrollment in ENHANCE-1 and ENHANCE-2 were based on expected continued improvements in the COVID-19 pandemic. Over the past quarter, our COVID-19 mitigation strategies have been helpful. However, the emergence of numerous COVID-19 related challenges, including new variants and increased infection and hospitalization rates across a number of countries, have put pressure on our recruitment timelines. With that said, let's review in more detail the enrollment status of both ENHANCE trials. As of the end of July, the ENHANCE-2 trial had 63% of patients randomized into the study. Including those currently entered in the run-in period, we expect ENHANCE-2 to be approximately 70% enrolled by the end of August. For the ENHANCE-1 trial, completing recruitment of the 48-week patient subset is a critical driver of the timeline for reporting top-line data from the study. As of the end of July, the 48-week subset in ENHANCE-1 had 70% of patients randomized into the study. Including those patients currently entered in the run-in period, we expect the 48-week subset to be approximately 80% enrolled by the end of August. Based on current enrollment and our projections, we are on pace to complete enrollment in both ENHANCE-2 and the critical timeline 48-week subset of ENHANCE-1 by the end of this year. The ENHANCE program continues to effectively enroll patients in part due to the COVID-19 mitigation strategies we implemented at the start of the program. These include planning the program to include broad geographic coverage of sites both in the U.S. and Europe to help manage the impact of local COVID impacts. Planning the program around minimally required on-site visits and adding flexibility around visits to ensure sites could follow their safety protocols. Developing individual site plans to prepare for events that may disrupt normal site operations, such as alternative methods for distributing study medications and for collecting data from patients. Providing for COVID-19 testing and personal protective equipment at all sites for adhering to safety protocols. Additionally, we amended ENHANCE-1 and ENHANCE-2 protocols to allow for up to 20% of patients to receive inhaled corticosteroids, or ICS, in addition to either a LAMA or a LABA. This modification broadens our patient pool and more accurately reflects the reality of clinical management during the COVID-19 pandemic. In phase II, ensifentrine demonstrated consistent lung function and symptom improvement, as well as a favorable safety profile with or without the use of ICS. Approximately 40% of patients in our 400-patient phase IIb study, 203, were receiving ICS. These data were presented as an abstract at the American Thoracic Society International Conference 2020. Based on our current enrollment and stated mitigation strategies due to COVID-19, our projections for reporting top-line data are in line with previous guidance, with ENHANCE-2 expected to report in the first half of 2022 and ENHANCE-1 in the second half of 2022. Should COVID-19 related challenges continue to increase, our models predict top-line data would be expected in Q3 2022 for ENHANCE-2 and Q4 2022 for ENHANCE-1. In support of our planned NDA submission, we have completed enrollment in our thorough QT study. This 32-patient study is designed to evaluate the effect of ensifentrine, if any, on cardiac conduction. We expect to report results by the end of this year. In 18 clinical trials to date involving over 1,300 subjects, ensifentrine has demonstrated a safety profile similar to placebo. As a reminder, based on the clinical safety data to date, no adverse events of interest are being assessed in the ENHANCE trials, and we were not required to include cardiac monitoring in the ENHANCE trials. Our goal remains the same, deliver ensifentrine to the millions of COPD patients who are not well-served by available treatments. Worldwide, there are over 384 million COPD patients, and COPD is the third leading cause of death. In the U.S., where Verona is preparing to commercialize ensifentrine, COPD affects more than 25 million patients, and sales in the maintenance COPD market total over $10 billion. Despite maximum therapy with existing medications, more than 1 million patients remain symptomatic. Outside the U.S., millions of COPD patients in Europe and China also remain symptomatic and in need of additional treatment. Turning to execution on our strategy to partner ensifentrine outside the U.S., we announced in June a strategic collaboration with Nuance Pharma, a Shanghai-based specialty pharmaceutical company, to which we granted the rights to develop and commercialize ensifentrine in Greater China, which includes mainland China, Taiwan, Hong Kong, and Macau. The agreement, with a potential value of up to $219 million, provided Verona with a $40 million upfront payment consisting of $25 million in cash and an equity interest currently valued at $50 million in Nuance Biotech, the parent company of Nuance Pharma. Verona is eligible to receive future milestone payments of up to $179 million upon achievement of certain clinical, regulatory, and commercial milestones. Verona is also entitled to receive tiered double-digit royalties on net sales in the licensed territories. We are excited about working with Nuance Pharma to bring a new and important treatment for COPD to these growing markets. Nuance's highly talented leadership team has extensive experience in developing and commercializing innovative products, including leading respiratory brands across Greater China. Nuance Pharma intends to meet with China's regulatory authorities to develop a plan to file an investigational new drug application for the treatment of COPD, and we look forward to updating everyone as we progress. We continue to build on our substantial clinical evidence to support the benefits of ensifentrine for the maintenance treatment of COPD. In May, Dr. Kathleen Rickard and Dr. Tara Rheault, Verona's Vice President of R&D, presented new subgroup analyses from phase IIb trials with nebulized ensifentrine in COPD at the American Thoracic Society International Conference 2021. The subgroup analysis demonstrated that ensifentrine showed improvement in lung function and quality of life in both severe and moderate COPD subgroups. Improvements in both subgroups were clinically meaningful after four weeks of treatment. In April, Verona published phase IIb clinical results with nebulized ensifentrine added on to maintenance bronchodilator therapy in symptomatic COPD patients in the peer-reviewed journal, International Journal of Chronic Obstructive Pulmonary Disease. We are pleased with our progress, and as we look ahead, we anticipate several important milestones, including presentations at the European Respiratory Society International Congress and CHEST, recording results of the TQT study, and importantly, reporting results of both the ENHANCE-1 and ENHANCE-2 trials in 2022. I will now turn the call over to Mark to review our second quarter financial results. Thank you, Dave, and good morning. We ended the second quarter of 2021 with $146 million in cash and equivalents, driven by an operating cash burn in Q2 of $20.2 million. After giving effect to the $25 million upfront payment from Nuance Pharma and the $8 million receipt from the U.K. tax credit program, both received in July, our pro forma cash and equivalents at June 30th was $179 million. We believe the combination of our cash position, expected cash receipts from U.K. tax credits, and potential borrowings under the $30 million debt financing facility secured in November 2020 will support our operations and current clinical development programs through at least 2023. For the six months ended June 30, 2021, the loss after tax was $43.4 million, compared to $21.4 million for the same period in the prior year. This represents a loss of $0.09 per ordinary share, or $0.72 per ADS for the six months ended June 30, 2021, compared to a loss of $0.20 per ordinary share or $1.60 per ADS in the same period of 2020. Research and development costs were $34.1 million for the six months ended June 30, 2021, compared to the $15.4 million reported for the same period in 2020. The increase of $18.7 million is primarily due to costs for the phase III clinical program and an increase in share-based compensation charges. General and administrative costs were $17.3 million for the six months ended June 30, 2021, compared to the $10 million reported for the same period of 2020. This increase of $7.3 million was driven primarily by an increase in share-based compensation charges, partially offset by executive change costs in the comparative period in 2020. The U.K. R&D tax credit for the six months ended June 30, 2021, was $5.9 million, compared to a credit of $3.5 million for the same period in 2020, increasing in line with the higher qualifying R&D expenditures incurred with the ENHANCE phase III program. We expect the tax credit to increase for the next two quarters as spending on the ENHANCE program continues. I'll now turn the call back over to the operator for the Q&A. We will now begin the question-and-answer session. To ask a question, press star then one on a touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, press star then two. At this time, we will pause momentarily to assemble our roster. The first question comes from Suji Jeong with Jefferies. Please go ahead. Hi. Good morning. Thanks for taking my question. I have questions about the enrollment for ENHANCE trial. Given that the studies were initiated at the end of September last year, what gives you confidence that the enrollment for the both trials may complete by the end of the year? Could you also tell us how many study sites are currently open? Also, what's the target number of sites for the both studies? Thank you. Hi, Suji. Great to speak with you this morning. Let me just give a few comments about enrollment and trajectory of enrollment. As in any trial, and especially one of this magnitude of sites and international coverage, although we started at the end of September, sites do come online at different times. Europe tends to be a bit lagged from the U.S., typically. Over that period of time, especially in the first two quarters or so, you saw sites coming online and we're building the recruitment in the site. I would say is we're in the middle or the trajectory that I guess is increasing, if you will, with sites that are substantially all up and running. We have, as we've kind of given you the insights as to the month-over-month type of recruitment that we're expecting to see, albeit it could be impacted by COVID-19, as we've discussed. We do have a record now of recruitment over the past quarter or so, of course, on a weekly basis. We see that trajectory getting us to completing the enrollment by the end of the year. I think as you see by the percentages and the movement from July to August, we're in that part of the recruitment curve that should get us there. Of course, we continue our mitigation plan, and we continue to work with all the sites to solve any local issues that they may have in order to continue enrollment. I think we have that confidence based on really where we are on recruitment and on our projections. As far as the number of sites as I think we've guided to, there are over 200 sites participating in the ENHANCE program overall. We have, of course, the vast majority of those sites up and running. Each one of those sites works through, at various times, any impacts from COVID-19. That may slow them down or not have a slowdown depending on the situation locally for them at any given time. As I mentioned, we have a great variety and span of geographic coverage. I think based on the sites, the number we have, the trajectory, we're seeing that we can complete the enrollment by the end of the year. Just a couple more questions. Could you tell us about the run-in period and how long that is? You said that the study will now include 20% of patients that would be on ICS. Was that amendment initiated by the company or was it at the request of FDA? Would that inclusion affect the statistical analysis plan? Right. As far as ICS, we initiated that change based on continued feedback from physicians, KOLs, that patients during the COVID-19 pandemic were being left on ICS as a perceived precautionary measure and maybe some protection from COVID-19. Of course, we looked at our data and felt that we can enroll those patients into the study, being on also a background of a LAMA or a LABA, and that we don't believe that will impact the primary endpoint, the secondary endpoint, based on the data we had accumulated to date in phase II. We don't see it impacting our statistical analysis plan in the study. Was there something else that I missed? The run-in period. How long- Oh, the run-in period. The 30 days. Oh, 30 days. Okay. Great. Thank you. The next question comes from Joon Lee with Truist Securities. Please go ahead. Good morning. This is Les Sulewski on for Joon Lee, and thank you for taking my questions. First, congratulations on establishing the validating partnership with Nuance in China. Can you first speak to the timelines for the NDA process by Nuance? Second, can you also talk about your progress on partnership discussions in other regions? Would you expect that they would have a similar composition to the one with Nuance? Right. Thanks for the questions. As far as the timeline in China, it may be a little bit premature. As I mentioned, we need to have the meeting with the China regulatory authorities, discuss our plan for the IND, and also our overarching plan for development in China. We want to wait for that feedback before we understand the timelines and in greater detail. Clearly, it's behind our process that's targeted in the U.S., nonetheless, we'll wait for that. As far as other BD development collaborations in other geographic areas, of course, we continue to do that. It's part of our stated strategy. We have ongoing outreach and discussions about that. We are also in no particular hurry. We want to make sure that the partner, the deal structure is representative of the underlying value of ensifentrine, which of course, we believe we achieved with the partnership with Nuance. Terms can be different and variable. Again, we're going to make sure that we feel that it is a deal structure that represents the value of ensifentrine. We'll continue to work on that through this year and into next year. Of course, I think the dynamic changes substantially as the data comes out as well. Thank you for that color. Last one from me is on the U.K. tax credits. They've somewhat become more material to your impact on the balance sheet. Can you outline the dynamics of these tax credits? How should we model these through enrollment completion as well as pipeline results? At what point do these tax credits taper off? Thank you. Mark, do you want to handle that? Yeah, sure. Thanks for that question. The U.K. tax credit program is one where the U.K. government allows us to accumulate our R&D costs on an annual basis. One a year, typically springtime, we'll do it after the audited results are complete. We do a submission to the U.K. government, and they wire transfer money to us. We just received the money in July related to the R&D spent in 2020. As we incur or continue to incur R&D costs throughout 2021, those amounts will be approved, and then we will make our submission again sometime early next year after the audited results are complete. The U.K. R&D tax credit program is changing in 2022, so there will likely be a lower reimbursement rate, if you will, against our R&D spend. I think as you're modeling, you could expect a growing level of R&D tax credit through 2021, and then it should drop pretty significantly in 2022. Great. Thank you. The next question comes from Edward Nash with Canaccord Genuity. Please go ahead. Good morning. Thank you for taking our question. This is Xinw ei for Edward. We would like to hear your thoughts from your perspective of Verona. What's the competitive landscape has changed or has there been any changes for ensifentrine? During the past year or one year and a half, what do you think might be the next close competitor for ensifentrine? Thank you. Great. Thanks for the call. I think I'm going to turn that over to Chris Martin, head of commercial, to comment on the competitive landscape. Thanks, Dave. As we look at the competitive landscape right now, there's nothing eminent in the pipeline that is as unique like ensifentrine. Remember that ensifentrine's the first dual bronchodilator anti-inflammatory in one molecule. When we look at the competitive landscape and what's on the horizon, there's nothing that looks like ensifentrine's profile. When we talk to KOLs and physicians in our market research, that's something that's very appealing to them and something of great need. A significant unmet need in the marketplace is this idea that they have three mechanisms that they can use with patients today, and they need something additional when these patients remain symptomatic. When we look at how the landscape looks today and how it will look when ensifentrine launches, we believe that ensifentrine will place and be in a very favorable position because of that mechanism of action. Also the clinical data set that we have which balances a very effective molecule on lung function and symptom improvement, but also with a safety profile that gives physicians confidence to try ensifentrine in symptomatic patients. Okay, great. Thank you. The next question comes from Andreas Argyrides with Wedbush Securities. Please go ahead. Hi, good morning, and thank you for taking our questions. This is Andreas on for Liana. Just a quick one on the near-term milestones. You have a couple of presentations at ERS and CHEST. If you could just give us a bit of a summary as to what we're going to see, anything incremental there? Thank you. Great. Thanks for that. Looks like we're working everyone into the call today. I'm going to ask Dr. Rickard to comment on our upcoming abstracts and publications. Right. Correct. Hello, this is Kathleen Rickard. For our presentations coming up, we have one at the European Respiratory Society meeting, which is at PK102, so that's our pharmacokinetic study, which basically looks at drug interactions and the data shows that we have really very little drug interaction with a drug that affects the liver. The second one is for CHEST 2021, which is October, that's basically looking at our safety and efficacy data from our seven-day trial for our metered- dose inhaler formulation, which basically shows again that we can deliver the medication by the MDI and that we show very strong bronchodilation in this study. It confirms what we've seen in our dry powder inhaler studies also. Those are the two that we have coming up in the near future. Fantastic. Okay. Thank you, and congrats on all the enrollment progress. Thank you. Again, if you would like to ask a question, press star then one to join the queue. The next question comes from Thomas Schrader with BTIG. Please go ahead. Hello, good morning. This is Sung Ji Nam subbing in for Tom Schrader. Could you guys provide a little more color on thinking about the commercial opportunity in China? I know that the market is very large in terms of the COPD market, but I assume the pricing will be different as well as the reimbursement landscape will be also complex. Could you just provide your thoughts on that, please? Thank you. Yes. No, thanks for the question. You're right. I think the market dynamics are different. Of course, in China pricing is different. They have different payer dynamics, private pay and government pay and that process has to evolve. As you noted, the number of patients in China is much greater and so that dynamic also plays into it. I think it's a little premature to understand the exact forecast and market in China, although we consider it to be substantial on a worldwide basis. I don't know if, Chris, you want to comment in addition to that from our collaboration with Nuance. I think Dave you covered it very well there. The one thing to keep in mind is one of the things that we see from a market standpoint is data out there suggests that the market for COPD medications within China is expected to more than double in the coming years. A lot of that is due to increased diagnosis of COPD and increased treatment and access to newer medications. Again, as Dave said, we expect this market to be a substantial market and we're working through how ensifentrine will fit in there from both a clinical and a commercial perspective with our partner. Great. Thank you, and congrats again on the progress so far. Thanks. This concludes our question-and-answer session. I'll now turn the conference back over to David Zaccardelli for any closing remarks. Thanks, operator. We'd like to thank you for your questions and thank the patients and healthcare professionals participating in the ENHANCE program. In August, we'll be presenting at several investor conferences, including BTIG, Wedbush, and Canaccord, and look forward to speaking to many of you then. I would like to thank our shareholders for their continued support and the dedicated and talented team at Verona for their commitment. Operator, that concludes today's call.